12:00 AM
 | 
Feb 15, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Stelara ustekinumab regulatory update

The Scottish Medicines Consortium recommended use of Johnson & Johnson's Stelara ustekinumab on the National Health Service (NHS) in Scotland to treat moderate to severe plaque psoriasis in adults who failed to respond to, have a contraindication to or are...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >